Galderma Group announces new phase II data on nemolizumab which demonstrates clinically meaningful benefits for children aged 2 to 11 with moderate-to-severe atopic dermatitis (CHF 149.60, 0.00)
Almirall is presenting a broad range of clinical and real‑world data across its portfolio at the 2026 AAD Annual Meeting (€12.06, +0.48)
Galderma Group to present latest updates on its innovations across its portfolio at 2026 American Academy of Dermatology Annual Meeting, March 27-31 in Denver, Colorado (CHF 142.50, 0.00)
Japan's MHLW approves Chugai Pharmaceutical's combination of Lunsumio and Polivy for relapsed or refractory large B-cell lymphoma (¥7947.0000, 0)
StreetAccount Sector Summary - Healthcare Post-Market
Genentech stops development of emugrobart in SMA; Cantor sees opportunity for Scholar Rock (CHF 305.70, 0.00)
StreetAccount Summary - Trading higher/lower: Japan mid-day
Sarepta announces screening and enrollment underway in ENDEAVOR Cohort 8 to evaluate enhanced immunosuppression regimen as part of ELEVIDYS gene therapy for non-ambulant individuals with Duchenne ($16.40, 0.00)
Roche announces phase III persevERA study in ER-positive advanced breast cancer did not meet its primary objective (CHF 341.20, 0.00)
Lilly announces publication of detailed ACHIEVE-3 trial results in The Lancet ($1028.83, 0.00)
Powered by FactSet Research Systems Inc.